Literature DB >> 1707255

Prospective, randomized trial of palliative treatment for unresectable cancer of the esophagus.

C E Reed1, W H Marsh, L S Carlson, C H Seymore, J M Kratz.   

Abstract

To evaluate the best method of palliation for obstructing nonresectable squamous cell carcinoma of the mid or distal esophagus, 27 patients were prospectively randomized to one of three treatment arms: (1) esophageal intubation with an Atkinson tube (AT, 10 patients), (2) esophageal intubation followed by radiation therapy (AT/RT, 8 patients), and (3) endoscopic laser therapy followed by irradiation (L/RT, 9 patients). Pretreatment characteristics were similar in the three groups. There was no procedure-related mortality. There were eight total complications related to the tube and none related to laser treatment (p = 0.02). Mean survival was 119 days in the AT group, 72 days in the AT/RT group, and 169 days in the L/RT arm (p = not significant). Quality of survival was most dependent on swallowing ability, and the swallowing score increased by 2.3 units in the AT group, 1.8 units in the AT/RT group, and 1.4 units in the L/RT group (p = not significant). Adding RT to laser therapy significantly increased time in treatment (mean, 38.7 days) when compared with the AT group (mean, 12.5 days) (p less than 0.001). However, only 1 patient required repeat laser ablation. It is concluded that AT and L/RT result in good palliation as measured by relief of dysphagia and survival time. However, morbidity of AT is significantly greater than that of L/RT. Laser and radiation therapy with a reduced total dosage of RT or with a change in fractionation schedule to limit treatment time is the preferred method of palliation.

Entities:  

Mesh:

Year:  1991        PMID: 1707255     DOI: 10.1016/0003-4975(91)90309-e

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Clinical application of modified Anyang type 2 esophageal intubation instrument--a new esophageal intubation method.

Authors:  X Han; Z S Nan; Y P Mao; Z J Ge; M S Chen; Y Duan
Journal:  J Tongji Med Univ       Date:  1995

Review 2.  Comparison of different treatments for unresectable esophageal cancer.

Authors:  C E Reed
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

3.  A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex).

Authors:  H S S Ho; H S Ong
Journal:  Surg Endosc       Date:  2004-02       Impact factor: 4.584

Review 4.  Advanced esophageal carcinoma.

Authors:  T E Lerut; P de Leyn; W Coosemans; D Van Raemdonck; P Cuypers; B Van Cleynenbreughel
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

Review 5.  Quality of life with carcinoma of the esophagus.

Authors:  G A Gelfand; R J Finley
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

Review 6.  Interventions for dysphagia in oesophageal cancer.

Authors:  Yingxue Dai; Chaoying Li; Yao Xie; Xudong Liu; Jianxin Zhang; Jing Zhou; Xiongfei Pan; Shujuan Yang
Journal:  Cochrane Database Syst Rev       Date:  2014-10-30

7.  Photodynamic therapy for middle-advanced stage upper gastrointestinal carcinomas: A systematic review and meta-analysis.

Authors:  Bo Chen; Li Xiong; Wei-Dong Chen; Xiao-Hua Zhao; Jun He; Yan-Wen Zheng; Fan-Hua Kong; Xi Liu; Zi-Jian Zhang; Xiong-Ying Miao
Journal:  World J Clin Cases       Date:  2018-11-06       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.